Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OrthoPediatrics ( (KIDS) ) has issued an update.
On April 2026, OrthoPediatrics disclosed that its executive officers plan to deliver a series of upcoming presentations to investors and analysts using a new 2026 investor deck. The materials outline the company’s exclusive focus on pediatric orthopedics, its history of consistent year-over-year growth excluding 2020, and its reach across more than 75 countries and all major U.S. children’s hospitals.
The presentation underscores OrthoPediatrics’ strategy of differentiating itself from larger, adult-focused incumbents by offering first-in-market pediatric-specific surgical solutions and a dedicated global sales force. It also highlights the company’s reliance on non-GAAP measures such as free cash flow and Adjusted EBITDA to assess core operating performance, signaling to stakeholders how management evaluates growth and profitability within a $6.2 billion global pediatric orthopedic market.
The most recent analyst rating on (KIDS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on OrthoPediatrics stock, see the KIDS Stock Forecast page.
Spark’s Take on KIDS Stock
According to Spark, TipRanks’ AI Analyst, KIDS is a Neutral.
The score is driven primarily by mixed financial performance: strong revenue growth and healthy gross margins are offset by ongoing losses and still-weak cash flow. The earnings call adds support via credible improvement guidance (EBITDA expansion and FCF breakeven target), while technicals are neutral-to-mixed and valuation is constrained by a negative P/E and no dividend.
To see Spark’s full report on KIDS stock, click here.
More about OrthoPediatrics
OrthoPediatrics is a specialized medical device company focused exclusively on pediatric orthopedic care, developing implants and technologies tailored to children’s unique clinical conditions. The company offers the broadest pediatric-specific portfolio in the industry, serves all top U.S. children’s hospitals through a global sales and distribution network, and supports extensive surgeon clinical education worldwide.
Its product suite spans trauma and deformity correction, scoliosis fusion and non-fusion implants, specialty bracing, sports medicine implants and enabling technologies, targeting a global pediatric orthopedic market estimated at $6.2 billion. OrthoPediatrics emphasizes innovation via internal R&D, acquisitions and partnerships, and positions itself as the only focused pediatric orthopedic player against larger incumbents that repurpose adult implants for children.
Average Trading Volume: 154,491
Technical Sentiment Signal: Sell
Current Market Cap: $370.1M
For an in-depth examination of KIDS stock, go to TipRanks’ Overview page.